E
Ionis Pharmaceuticals, Inc.
IONS
$37.31
-$0.31-0.82%
E
Sell
5/3/2024Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and total return index.
D
Sell
2/22/2024Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 2/22/2024 due to a noticeable decline in the efficiency index and valuation index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 2/22/2024 due to a noticeable decline in the efficiency index and valuation index.
D
Sell
11/6/2023Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 11/6/2023 due to a noticeable increase in the efficiency index and volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 11/6/2023 due to a noticeable increase in the efficiency index and volatility index.
D
Sell
8/21/2023Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D- from E+ on 8/21/2023 due to an increase in the volatility index, total return index and growth index. Total revenue increased 44.35% from $130.52M to $188.41M, earnings per share increased from -$0.871 to -$0.6, and operating cash flow increased 27.34% from -$133.99M to -$97.36M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D- from E+ on 8/21/2023 due to an increase in the volatility index, total return index and growth index. Total revenue increased 44.35% from $130.52M to $188.41M, earnings per share increased from -$0.871 to -$0.6, and operating cash flow increased 27.34% from -$133.99M to -$97.36M.
E
Sell
3/14/2023Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the solvency index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the solvency index and total return index.
D
Sell
2/24/2023Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D+ on 2/24/2023 due to a significant decline in the growth index, efficiency index and solvency index. Operating cash flow declined 719.5% from -$24.43M to -$200.2M, EBIT declined 248.22% from -$59.15M to -$205.99M, and earnings per share declined from -$0.331 to -$0.3718.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D+ on 2/24/2023 due to a significant decline in the growth index, efficiency index and solvency index. Operating cash flow declined 719.5% from -$24.43M to -$200.2M, EBIT declined 248.22% from -$59.15M to -$205.99M, and earnings per share declined from -$0.331 to -$0.3718.
D
Sell
11/29/2022Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 11/29/2022 due to a decline in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 11/29/2022 due to a decline in the volatility index and total return index.
C
Hold
11/11/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D on 11/11/2022 due to a significant increase in the growth index, efficiency index and total return index. Earnings per share increased from -$0.7415 to -$0.331, net income increased 55.3% from -$105.14M to -$46.99M, and EBIT increased 30.83% from -$85.51M to -$59.15M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D on 11/11/2022 due to a significant increase in the growth index, efficiency index and total return index. Earnings per share increased from -$0.7415 to -$0.331, net income increased 55.3% from -$105.14M to -$46.99M, and EBIT increased 30.83% from -$85.51M to -$59.15M.
D
Sell
7/25/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 7/25/2022 due to an increase in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 7/25/2022 due to an increase in the volatility index and total return index.
D
Sell
5/31/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and total return index.
E
Sell
5/13/2022Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/6/2022Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 5/6/2022 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $1.4063 to -$0.4602, EBIT declined 127.08% from $212.31M to -$57.5M, and operating cash flow declined 115.54% from $203.69M to -$31.65M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 5/6/2022 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $1.4063 to -$0.4602, EBIT declined 127.08% from $212.31M to -$57.5M, and operating cash flow declined 115.54% from $203.69M to -$31.65M.
D
Sell
5/4/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D on 4/20/2022 due to a decline in the valuation index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to E+ from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
2/28/2022Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 2/28/2022 due to a significant increase in the growth index, solvency index and total return index. Operating cash flow increased 466.51% from -$55.57M to $203.69M, EBIT increased 355.65% from -$83.05M to $212.31M, and earnings per share increased from -$0.5843 to $1.4063.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 2/28/2022 due to a significant increase in the growth index, solvency index and total return index. Operating cash flow increased 466.51% from -$55.57M to $203.69M, EBIT increased 355.65% from -$83.05M to $212.31M, and earnings per share increased from -$0.5843 to $1.4063.
D
Sell
11/18/2021Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 11/18/2021 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 2.22 to 2.43, total capital declined 2.8% from $1.89B to $1.84B, and net income declined 1.97% from -$80.88M to -$82.47M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 11/18/2021 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 2.22 to 2.43, total capital declined 2.8% from $1.89B to $1.84B, and net income declined 1.97% from -$80.88M to -$82.47M.
D
Sell
8/6/2021Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 8/6/2021 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 32.14% from -$85.27M to -$57.87M, total capital increased 16.79% from $1.62B to $1.89B, and total revenue increased 12.67% from $111.61M to $125.75M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 8/6/2021 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 32.14% from -$85.27M to -$57.87M, total capital increased 16.79% from $1.62B to $1.89B, and total revenue increased 12.67% from $111.61M to $125.75M.
D
Sell
5/19/2021Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the solvency index, volatility index and growth index. EBIT declined 1,304.05% from $7.08M to -$85.27M, operating cash flow declined 155.79% from $97.98M to -$54.66M, and total revenue declined 61.55% from $290.28M to $111.61M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the solvency index, volatility index and growth index. EBIT declined 1,304.05% from $7.08M to -$85.27M, operating cash flow declined 155.79% from $97.98M to -$54.66M, and total revenue declined 61.55% from $290.28M to $111.61M.
D
Sell
2/26/2021Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from C- on 2/26/2021 due to a significant decline in the growth index, efficiency index and solvency index. Net income declined 999.63% from -$30.94M to -$340.27M, earnings per share declined from -$0.2222 to -$2.4304, and debt to equity increased from 0.58 to 0.98.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from C- on 2/26/2021 due to a significant decline in the growth index, efficiency index and solvency index. Net income declined 999.63% from -$30.94M to -$340.27M, earnings per share declined from -$0.2222 to -$2.4304, and debt to equity increased from 0.58 to 0.98.
C
Hold
12/28/2020Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 12/28/2020 due to an increase in the volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 12/28/2020 due to an increase in the volatility index.
D
Sell
12/10/2020Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 12/10/2020 due to a decline in the total return index, valuation index and growth index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 12/10/2020 due to a decline in the total return index, valuation index and growth index.
C
Hold
10/2/2020Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 10/2/2020 due to a decline in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 10/2/2020 due to a decline in the volatility index and total return index.
C
Hold
8/7/2020Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 8/7/2020 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.35 to -$0.23, EBIT increased 15.33% from -$61.13M to -$51.75M, and total revenue increased 9.13% from $133.37M to $145.54M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 8/7/2020 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.35 to -$0.23, EBIT increased 15.33% from -$61.13M to -$51.75M, and total revenue increased 9.13% from $133.37M to $145.54M.
C
Hold
5/8/2020Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 5/8/2020 due to a significant decline in the valuation index, total return index and efficiency index. Net income declined 126.15% from $184.42M to -$48.23M, and total capital declined 4.16% from $2.47B to $2.37B.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 5/8/2020 due to a significant decline in the valuation index, total return index and efficiency index. Net income declined 126.15% from $184.42M to -$48.23M, and total capital declined 4.16% from $2.47B to $2.37B.
C
Hold
8/13/2019Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C from C+ on 8/13/2019 due to a significant decline in the growth index, total return index and valuation index. Operating cash flow declined 125.17% from $107.71M to -$27.11M, EBIT declined 115.49% from $121.54M to -$18.83M, and earnings per share declined from $0.62 to -$0.01.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C from C+ on 8/13/2019 due to a significant decline in the growth index, total return index and valuation index. Operating cash flow declined 125.17% from $107.71M to -$27.11M, EBIT declined 115.49% from $121.54M to -$18.83M, and earnings per share declined from $0.62 to -$0.01.
C
Hold
7/5/2019Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C+ from B- on 7/5/2019 due to a noticeable decline in the total return index, valuation index and volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C+ from B- on 7/5/2019 due to a noticeable decline in the total return index, valuation index and volatility index.
B
Buy
6/17/2019Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to B- from C+ on 6/17/2019 due to an increase in the volatility index and valuation index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to B- from C+ on 6/17/2019 due to an increase in the volatility index and valuation index.
C
Hold
5/30/2019Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C+ from B- on 5/30/2019 due to a decline in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C+ from B- on 5/30/2019 due to a decline in the total return index.
B
Buy
5/15/2019Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to B- from C on 5/15/2019 due to a significant increase in the growth index, total return index and efficiency index. EBIT increased 949.07% from $11.59M to $121.54M, total revenue increased 54.71% from $192.12M to $297.21M, and total capital increased 12.08% from $1.83B to $2.06B.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to B- from C on 5/15/2019 due to a significant increase in the growth index, total return index and efficiency index. EBIT increased 949.07% from $11.59M to $121.54M, total revenue increased 54.71% from $192.12M to $297.21M, and total capital increased 12.08% from $1.83B to $2.06B.
C
Hold
3/6/2019Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from D+ on 3/6/2019 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 7,120.75% from -$4.56M to $320.08M, and total capital increased 24.01% from $1.48B to $1.83B.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from D+ on 3/6/2019 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 7,120.75% from -$4.56M to $320.08M, and total capital increased 24.01% from $1.48B to $1.83B.
D
Sell
11/8/2018Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 11/8/2018 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2947 to -$0.0322, EBIT increased 63.06% from -$50.28M to -$18.57M, and total revenue increased 23.48% from $117.75M to $145.4M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 11/8/2018 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2947 to -$0.0322, EBIT increased 63.06% from -$50.28M to -$18.57M, and total revenue increased 23.48% from $117.75M to $145.4M.
D
Sell
5/10/2018Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 5/10/2018 due to a large decline in the growth index, solvency index and volatility index. EBIT declined 270.9% from -$890 to -$3.3M, earnings per share declined from $0.0216 to -$0.0113, and operating cash flow declined 35.47% from $20.4M to $13.17M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 5/10/2018 due to a large decline in the growth index, solvency index and volatility index. EBIT declined 270.9% from -$890 to -$3.3M, earnings per share declined from $0.0216 to -$0.0113, and operating cash flow declined 35.47% from $20.4M to $13.17M.
D
Sell
4/24/2018Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 4/24/2018 due to an increase in the volatility index and total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 4/24/2018 due to an increase in the volatility index and total return index.
D
Sell
4/9/2018Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 4/9/2018 due to a decline in the total return index, efficiency index and growth index. EBIT declined 106.4% from $13.91M to -$890, and operating cash flow declined 28.97% from $28.72M to $20.4M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 4/9/2018 due to a decline in the total return index, efficiency index and growth index. EBIT declined 106.4% from $13.91M to -$890, and operating cash flow declined 28.97% from $28.72M to $20.4M.
D
Sell
12/15/2017Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 12/15/2017 due to a large decline in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C- on 12/15/2017 due to a large decline in the total return index.
C
Hold
11/24/2017Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 11/24/2017 due to a noticeable decline in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to C- from C on 11/24/2017 due to a noticeable decline in the total return index.
C
Hold
11/9/2017Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 11/9/2017 due to a major increase in the growth index, solvency index and valuation index. Operating cash flow increased 1,115.4% from $2.36M to $28.72M, EBIT increased 932.38% from -$1.67M to $13.91M, and earnings per share increased from -$0.0904 to -$0.0078.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 11/9/2017 due to a major increase in the growth index, solvency index and valuation index. Operating cash flow increased 1,115.4% from $2.36M to $28.72M, EBIT increased 932.38% from -$1.67M to $13.91M, and earnings per share increased from -$0.0904 to -$0.0078.
C
Hold
9/25/2017Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 9/25/2017 due to a substantial increase in the total return index and efficiency index. Total capital increased 2.76% from $797.71M to $819.7M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 9/25/2017 due to a substantial increase in the total return index and efficiency index. Total capital increased 2.76% from $797.71M to $819.7M.
D
Sell
7/5/2017Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 7/5/2017 due to a noticeable increase in the total return index and volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 7/5/2017 due to a noticeable increase in the total return index and volatility index.
D
Sell
5/12/2017Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 5/12/2017 due to a major decline in the growth index and total return index. Earnings per share declined from $0.208 to $0.0282, EBIT declined 66.72% from $42.32M to $14.08M, and total revenue declined 31.21% from $160.35M to $110.3M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 5/12/2017 due to a major decline in the growth index and total return index. Earnings per share declined from $0.208 to $0.0282, EBIT declined 66.72% from $42.32M to $14.08M, and total revenue declined 31.21% from $160.35M to $110.3M.
D
Sell
5/1/2017Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 5/1/2017 due to an increase in the total return index and volatility index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 5/1/2017 due to an increase in the total return index and volatility index.
D
Sell
3/23/2017Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 3/23/2017 due to a decline in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 3/23/2017 due to a decline in the total return index.
D
Sell
3/8/2017Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 3/8/2017 due to a major increase in the growth index, total return index and volatility index. Earnings per share increased from $0.06 to $0.208, EBIT increased 151.77% from $16.81M to $42.32M, and total revenue increased 44.55% from $110.93M to $160.35M.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D+ from D on 3/8/2017 due to a major increase in the growth index, total return index and volatility index. Earnings per share increased from $0.06 to $0.208, EBIT increased 151.77% from $16.81M to $42.32M, and total revenue increased 44.55% from $110.93M to $160.35M.
D
Sell
10/10/2016Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 10/10/2016 due to an increase in the total return index, volatility index and valuation index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to D from D- on 10/10/2016 due to an increase in the total return index, volatility index and valuation index.
D
Sell
8/12/2016Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 8/12/2016 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 2.57 to 3.71.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D- from D on 8/12/2016 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 2.57 to 3.71.
D
Sell
3/11/2016Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 99.67% from -$35.78M to -$71.43M, and total capital declined 4.95% from $717.48M to $681.95M.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 99.67% from -$35.78M to -$71.43M, and total capital declined 4.95% from $717.48M to $681.95M.
D
Sell
1/19/2016Downgrade
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C on 1/19/2016 due to a substantial decline in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was downgraded to D+ from C on 1/19/2016 due to a substantial decline in the total return index.
C
Hold
1/8/2016Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 1/8/2016 due to a substantial increase in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C from C- on 1/8/2016 due to a substantial increase in the total return index.
C
Hold
12/30/2015Upgraded
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 12/30/2015 due to an increase in the total return index.
Ionis Pharmaceuticals, Inc. (IONS) was upgraded to C- from D+ on 12/30/2015 due to an increase in the total return index.
D
Sell
11/13/2015Downgrade
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C on 11/13/2015 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 207.82% from $44.65M to -$48.14M, earnings per share declined from $0.2872 to -$0.2982, and total revenue declined 59.21% from $120.43M to $49.12M.
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C on 11/13/2015 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 207.82% from $44.65M to -$48.14M, earnings per share declined from $0.2872 to -$0.2982, and total revenue declined 59.21% from $120.43M to $49.12M.
C
Hold
8/7/2015Upgraded
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from D+ on 8/7/2015 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 92.43% from $62.58M to $120.43M, debt to equity declined from 1.42 to 1.32, and total capital increased 3.94% from $738.12M to $767.22M.
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from D+ on 8/7/2015 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 92.43% from $62.58M to $120.43M, debt to equity declined from 1.42 to 1.32, and total capital increased 3.94% from $738.12M to $767.22M.
D
Sell
6/5/2015Downgrade
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C- on 6/5/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C- on 6/5/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold
5/8/2015Downgrade
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to C- from C on 5/8/2015 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 187.75% from $10.63M to -$9.33M, operating cash flow declined 160.59% from $70.68M to -$42.83M, and earnings per share declined from $0.2528 to -$0.1405.
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to C- from C on 5/8/2015 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 187.75% from $10.63M to -$9.33M, operating cash flow declined 160.59% from $70.68M to -$42.83M, and earnings per share declined from $0.2528 to -$0.1405.
C
Hold
3/5/2015Upgraded
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from C- on 3/5/2015 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 3,536.01% from $1.94M to $70.68M, and total revenue increased 92.59% from $44.06M to $84.86M.
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from C- on 3/5/2015 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 3,536.01% from $1.94M to $70.68M, and total revenue increased 92.59% from $44.06M to $84.86M.
C
Hold
8/7/2014Upgraded
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C- from D+ on 8/7/2014 due to an increase in the growth index and efficiency index. Total revenue increased 102.68% from $28.16M to $57.08M, and operating cash flow increased 5.22% from -$32.33M to -$34.02M.
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C- from D+ on 8/7/2014 due to an increase in the growth index and efficiency index. Total revenue increased 102.68% from $28.16M to $57.08M, and operating cash flow increased 5.22% from -$32.33M to -$34.02M.
D
Sell
5/9/2014Downgrade
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C- on 5/9/2014 due to a substantial decline in the growth index, efficiency index and total return index. Total revenue declined 33.35% from $42.25M to $28.16M, and total capital declined 0.59% from $610.96M to $607.33M.
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to D+ from C- on 5/9/2014 due to a substantial decline in the growth index, efficiency index and total return index. Total revenue declined 33.35% from $42.25M to $28.16M, and total capital declined 0.59% from $610.96M to $607.33M.
C
Hold
5/5/2014Downgrade
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to C- from C on 5/5/2014 due to a major decline in the total return index and efficiency index. Total capital declined 3.37% from $632.28M to $610.96M, and net income declined 1.2% from -$24.57M to -$24.28M.
Isis Pharmaceuticals, Inc. (ISIS) was downgraded to C- from C on 5/5/2014 due to a major decline in the total return index and efficiency index. Total capital declined 3.37% from $632.28M to $610.96M, and net income declined 1.2% from -$24.57M to -$24.28M.
C
Hold
2/28/2014Upgraded
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from C- on 2/28/2014 due to an increase in growth and solvency. EBIT increased 219.61% from -$7.93M to -$25.34M, operating cash flow increased 189.45% from $22.74M to $65.82M, and earnings per share increased from -$0.0933 to -$0.2132.
Isis Pharmaceuticals, Inc. (ISIS) was upgraded to C from C- on 2/28/2014 due to an increase in growth and solvency. EBIT increased 219.61% from -$7.93M to -$25.34M, operating cash flow increased 189.45% from $22.74M to $65.82M, and earnings per share increased from -$0.0933 to -$0.2132.
NASDAQ
05/17/2024 4:00PM Eastern
Quotes delayed
